
Medsafe approves Luxturna
Years of campaigning, led by consultant ophthalmologist Associate Professor Andrea Vincent from the University of Auckland, have paid off with the Medicines and Medical Devices Safety Authority’s (Medsafe’s) approval of Luxturna (voretigene neparvovec 0.05mg/mL) to treat patients with RPE65-related













